Biodesix, Biognosys Collaborate
News Jul 30, 2015
As Biodesix® continues to expand its collaborations with pharmaceutical companies and key opinion leaders in oncology to bring novel blood-based tests to market, the inclusion of Biognosys’ technology will offer new ways to rapidly discover biomarkers with Biodesix’ proven analytical platform. Biognosys’ HRM-MS™, the next generation high-content proteomics technology, provides reproducible and accurate quantification of thousands of proteins and helps researchers identify clinically meaningful differences between specific groups of patients. Compared to other mass spectrometry labeling approaches, the sample preparation is much simpler (no chemistry involved, no fractionation necessary) and there are no limitations on the number of samples that can be analyzed.
The foundation of Biodesix’ proteomic tests is based on combining deep MALDI-TOF mass spectrometry data with deep learning principles to extract the relevant molecular information from patient blood samples and correlating it to clinical outcomes. With the addition of HRM-MS technology, Biodesix gains the ability to develop and validate a wider array of diagnostic tests and companion diagnostics, as well as a way to understand the biology contained within tests developed via the hypothesis-independent methodology.
Biodesix has two fully commercialized tests, GeneStrat™ and VeriStrat®, which provide oncologists with clinically relevant information about the patient’s tumor profile and disease aggressiveness within 72 hours. The company’s test development efforts are focused on addressing clinical unmet needs in oncology, utilizing a range of platforms including MALDI-TOF mass spectrometry, droplet digital PCR and NGS and now HRM-MS technology.
“HRM-MS technology is a tool to help Biodesix decipher actionable signals in patients’ blood, helping physicians choose the right therapy based on the patient’s molecular signature. Biognosys’ HRM technology ideally complements our hypothesis-independent approach,” said Biodesix’ CEO, David Brunel. “This collaboration gives us access to cutting edge mass spectrometric technology that will further advance our ability to develop assays, now including those that rely on high-content protein quantification.”
“By combining our proven and comprehensive protein quantification technology with Biodesix’ understanding of the clinical research and diagnostics market, we can identify more clinically relevant classifiers and biomarkers,” said Oliver Rinner, Biognosys’ CEO. “We are excited to team up with Biodesix and strive to be the company that provides the best possible solutions to support researchers in their protein analysis needs.”
Patients in a new Northwestern Medicine study were able to comprehend words that were written but not said aloud. They could write the names of things they saw but not verbalize them. This provides an insight into the brain degeneration that defines the rare dementia termed primary progressive aphasia.